Table 1.
Patient characteristics according to VAT, SAT, and IMAT areas
| Characteristic | All (N = 31) | VAT | P value | SAT | P value | IMAT | P value | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Low (N = 12) | High (N = 19) | Low (N = 12) | High (N = 19) | Low (N = 5) | High (N = 26) | |||||
| Age, N (%) | 0.842 | 0.842 | 0.133* | |||||||
| < 60 years | 20 (64.5) | 8 (66.7) | 12 (63.2) | 8 (66.7) | 12 (63.2) | 5 (100) | 15 (57.7) | |||
| ≥ 60 years | 11 (35.5) | 4 (33.3) | 7 (36.8) | 4 (33.3) | 7 (36.8) | 0 (0) | 11 (42.3) | |||
| Histology at diagnosis, N (%) | 0.917* | 0.917* | 1.000* | |||||||
| High-grade serous carcinoma | 24 (77.4) | 9 (75.0) | 15 (78.9) | 9 (75.0) | 15 (78.9) | 5 (100) | 19 (73.1) | |||
| Low-grade serous carcinoma | 1 (3.2) | 0 (0) | 1 (5.3) | 0 (0) | 1 (5.3) | 0 (0) | 1 (3.8) | |||
| Endometrioid | 2 (6.5) | 1 (8.3) | 1 (5.3) | 1 (8.3) | 1 (5.3) | 0 (0) | 2 (7.7) | |||
| Clear cell | 3 (9.7) | 1 (8.3) | 2 (10.5) | 1 (8.3) | 2 (10.5) | 0 (0) | 3 (11.5) | |||
| Mucinous | 1 (3.2) | 1 (8.3) | 0 (0) | 1 (8.3) | 0 (0) | 0 (0) | 1 (3.8) | |||
| ECOG performance status, N (%) | 0.644* | 0.644* | 0.656* | |||||||
| 0 | 8 (25.8) | 2 (16.7) | 6 (31.6) | 2 (16.7) | 6 (31.6) | 2 (40) | 6 (23.1) | |||
| 1 | 22 (71.0) | 10 (83.3) | 12 (63.2) | 10 (83.3) | 12 (63.2) | 3 (60) | 19 (73.1) | |||
| 2 | 1 (3.2) | 0 (0) | 1 (5.3) | 0 (0) | 1 (5.3) | 0 (0) | 1 (3.8) | |||
| Number of previous chemotherapy lines, N (%) | 0.763 | 1.000 | 0.800* | |||||||
| 1–2 lines | 7 (22.6) | 3 (25) | 4 (21.1) | 3 (25) | 4 (21.1) | 1 (20) | 6 (23.1) | |||
| 3–6 lines | 19 (61.3) | 8 (66.7) | 11 (57.9) | 7 (58.3) | 12 (63.2) | 4 (80) | 15 (57.7) | |||
| > 6 lines | 5 (16.1) | 1 (8.3) | 4 (21.1) | 2 (16.7) | 3 (15.8) | 0 (0) | 5 (19.2) | |||
| Interval between last chemotherapy and disease progression, N (%) | 0.676 | 0.676 | 0.562* | |||||||
| < 3 months | 24 (77.4) | 10 (83.3) | 14 (73.7) | 10 (83.3) | 14 (73.7) | 5 (100) | 19 (73.1) | |||
| ≥ 3 months and < 6 months | 7 (22.6) | 2 (16.7) | 5 (26.3) | 2 (16.7) | 5 (26.3) | 0 (0) | 7 (26.9) | |||
| Dosage of apatinib, mean ± SD, g | 69.86 ± 41.38 | 55.47 ± 24.84 | 78.95 ± 47.46 | 0.049 | 56.41 ± 24.02 | 78.36 ± 48.00 | 0.034 | 42.35 ± 16.23 | 75.15 ± 42.81 | 0.096 |
Abbreviations: N number, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, IMAT intermuscular adipose tissue, FIGO International Federation of Gynecology and Obstetrics, ECOG Eastern Cooperative Oncology Group, SD standard deviation, g gram
*Fisher’s exact tests